US FDA approves Roche's Itovebi in combo with palbociclib & fulvestrant to treat advanced hormone receptor─positive, ...
Roche announced that the United States Food and Drug Administration (FDA) approved Itovebi (inavolisib), in combination with palbociclib (Ibrance) and fulvestrant, for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)- …